Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center
Articles
Final Thoughts on the Management of mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Additional Emerging Therapies for Progressive mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Emerging Agents for Progressive mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Sequencing After Frontline I/O Based Regimen for mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Clinical Trials for Relapsed/Refractory mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Upcoming Combination Trials for mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
I/O Therapy After Progression on I/O for mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Role of TKI After Progression on I/O for mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Review of the COSMIC 021 Study for mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Introduction and Review of CheckMate 9ER for Metastatic RCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
